Integra LifeSciences Reports Second Quarter 2025 Financial Results

Core Insights - Integra LifeSciences Holdings Corporation reported a total revenue of $415.6 million for Q2 2025, reflecting a decrease of 0.6% on a reported basis and 1.4% on an organic basis compared to the previous year [5][9] - The company experienced a GAAP net loss of $484.1 million, or $6.31 per diluted share, primarily due to a goodwill impairment charge of $511 million [6][9] - Adjusted net income for the quarter was $34.4 million, or $0.45 per diluted share, down from $49.0 million, or $0.63 per diluted share, in the prior year [6][9] Financial Performance - Total reported revenues decreased to $415.6 million, with a GAAP gross margin of 50.4%, down from 54.0% in Q2 2024 [5][6] - Adjusted gross margin was 60.7%, compared to 65.2% in the prior year [5][6] - Adjusted EBITDA for Q2 2025 was $71.2 million, representing 17.1% of revenue, down from $83.8 million, or 20.0% of revenue, in the prior year [5][6] Segment Performance - Codman Specialty Surgical, which accounts for approximately 70% of revenues, reported total revenues of $304.0 million, showing a reported growth of 0.7% but an organic decline of 0.3% compared to Q2 2024 [7] - Tissue Technologies, making up about 30% of revenues, saw total revenues of $111.6 million, reflecting a reported and organic decline of 4.1% compared to the same quarter last year [11] Operational Updates - The company has completed the assessment phase at all manufacturing sites as part of its Compliance Master Plan and is focused on remediation efforts [4] - Cash flow from operations for the quarter was $8.9 million, with total balance sheet debt at $1.85 billion and net debt at $1.59 billion [11][12] Guidance and Outlook - For Q3 2025, the company expects reported revenues in the range of $410 million to $420 million, indicating reported growth of 7.7% to 10.3% and organic growth of 7.3% to 9.9% [13] - The full-year revenue guidance has been updated to a range of $1.655 billion to $1.680 billion, representing reported growth of 2.8% to 4.3% and organic growth of 0.6% to 2.1% [14]